Owlstone Medical Raises $27 Million in Series E Funding to Advance Breath Biopsy Diagnostics
Owlstone Medical, a Cambridge-based pioneer in breath-based diagnostics, has raised $27 million in the first close of its Series E funding round. The investment will support the continued development and commercialization of the company’s Breath Biopsy® platform, aimed at detecting diseases through non-invasive breath analysis.
The funding round was led by Ventura Capital, with participation from Aviva Ventures, Horizons Ventures, and the Bill & Melinda Gates Foundation. This latest investment underscores growing confidence in Owlstone’s technology and its potential to transform early disease detection across multiple therapeutic areas.
Owlstone Medical’s Breath Biopsy® platform uses breath samples to detect volatile organic compounds (VOCs) that serve as biomarkers for various diseases. The company is currently focusing on developing diagnostic tests for lung cancer, liver disease, and digestive disorders, aiming to improve early diagnosis and patient outcomes.
The newly acquired funds will accelerate clinical trials, enhance manufacturing capabilities, and support regulatory approvals for Owlstone’s diagnostic products. The company also plans to develop point-of-care devices that enable real-time breath analysis in clinical settings, further enhancing accessibility and efficiency.
Billy Boyle, CEO of Owlstone Medical, highlighted the importance of the funding, stating that it will allow the company to advance its mission of saving lives through non-invasive diagnostics. Boyle emphasized that breath-based diagnostics have the potential to revolutionize healthcare by providing accurate and early disease detection without the need for invasive procedures.
The investment from the Bill & Melinda Gates Foundation is particularly significant, reflecting the foundation’s commitment to advancing global health technologies. Owlstone’s platform is expected to play a crucial role in low-resource settings, where access to traditional diagnostic tools is often limited.
Owlstone Medical’s innovative approach has already garnered attention from leading healthcare providers and research institutions worldwide. The company’s technology is being integrated into clinical studies and pilot programs, demonstrating its versatility and effectiveness in disease detection and monitoring.
With the latest funding, Owlstone Medical is well-positioned to expand its product offerings, enhance its technological capabilities, and bring breath-based diagnostics to a global market. The company’s advancements are set to make a significant impact on the early diagnosis and treatment of life-threatening diseases.
